Skip to main content

Pipeline Update from BioPorto

Written by Customer Service on . Posted in Public Companies.

March 3, 2021Announcement no. 3Pipeline Update from BioPortoBioPorto expects to complete its clinical study and submit a De Novo application to the FDA for pediatric use of The NGAL Test™ this summer.BioPorto awaits US test results for the rapid gRAD-based SARS-CoV-2 assay; if positive, the Company will proceed towards EUA and CE mark in the second quarter of 2021.In 2020, BioPorto A/S (BioPorto) began enrolling in a US clinical study for pediatric use of The NGAL Test for the risk assessment of acute kidney injury (AKI). The Company also undertook development of a novel SARS-CoV-2 viral test based on BioPorto’s Generic Rapid Assay Device (gRAD) platform.US application for The NGAL Test for pediatric AKI expected this summerBioPorto’s studies of The NGAL Test that don’t require hospital enrollment are being finalized according to schedule. However, the study of critically ill (hospitalized) pediatric patients continues slowly due to delays caused by the second and third waves of the COVID-19 pandemic.As of the beginning of March 2021, eight US hospitals have successfully been recruited to participate in the pediatric trial of NGAL, and BioPorto is continuing to add new sites to boost enrollment. Subject to further changes brought about by COVID-19, the Company expects to complete its pivotal study this summer and submit a De Novo 510(k) application to the US Food and Drug Administration (FDA).Test results for gRAD-based SARS-CoV-2 test are pendingBased on the gRAD platform, BioPorto has developed a point-of-care test for SARS-CoV-2 designed to quickly and easily identify infected patients using a non-invasive sample. In late December 2020, BioPorto provided its first kits to the University of California, Davis (US) for testing with samples from COVID-19 patients.After encountering initial issues in the trial, development teams on both sides of the Atlantic have worked together to resolve the challenges and BioPorto is currently awaiting outcome of the new testing.  If results support BioPorto’s laboratory findings, the Company will progress with plans to submit an Emergency Use Authorization (EUA) request with the FDA and a CE mark filing in Europe in the second quarter of 2021. To further support the CE mark application, BioPorto is also evaluating options for conducting additional testing at clinical sites in Europe.For further information, please contact:Peter Mørch Eriksen, CEOOle Larsen, CFOTelephone + 45 4529 0000, email investor@bioporto.comAbout BioPortoBioPorto is an in vitro diagnostics company that provides tests and antibodies to clinicians and researchers around the world. We use our antibody and assay expertise to transform novel research tools into clinically actionable biomarkers that can make a difference in patients’ lives. BioPorto is headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange [CPH:BIOPOR].Attachment2021 03 03 – Announcement no. 3

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.